Rilapladib (SB 659032) is a potent and selective inhibitor of Lp-PLA2 (IC50 = 230 pM) and a platelet-activating factor receptor antagonist. This small molecule is a valuable research tool for investigating atherosclerosis and neuroinflammation in both cellular and animal models.